NCT06835387 Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors Status RECRUITING Phase PHASE2
NCT06825624 ARTEMIS-102: HS-20093 Combinations in Patients with Advanced Metastatic Colorectal Cancer Status RECRUITING Phase PHASE1
NCT06820463 A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer Status RECRUITING Phase PHASE2
NCT06780111 Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) Status RECRUITING Phase PHASE1/PHASE2
NCT06771622 Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1/PHASE2
NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors Status RECRUITING Phase PHASE1/PHASE2
NCT06733038 FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients. Status RECRUITING Phase PHASE3
NCT06628310 A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Status RECRUITING Phase PHASE2
NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Status ACTIVE_NOT_RECRUITING Phase PHASE3
NCT06607185 A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06586515 MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors Status RECRUITING Phase PHASE1
NCT06576037 Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin Status RECRUITING Phase PHASE1
NCT06490913 Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes Status NOT_YET_RECRUITING Phase PHASE2
NCT06469944 Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) Status RECRUITING Phase PHASE1/PHASE2
NCT06381154 Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer Status RECRUITING Phase PHASE2
NCT06328738 ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT06317662 Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Status RECRUITING Phase PHASE2
NCT06268015 Botensilimab and Balstilimab Optimization in Colorectal Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT06259058 Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Cancer Status NOT_YET_RECRUITING Phase PHASE1/PHASE2
NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Status RECRUITING Phase PHASE2